Photo from Oxford BioTherapeutics/Linkedin
Jul 11, 2023, 15:33
First patient dosed in combination trial of OBT076 and CPI Balstilimab – Oxford BioTherapeutics
We are pleased to announce that the first patient has been dosed in a Phase 1b combination trial evaluating OBT076 and Agenus’ PD1 checkpoint inhibitor Balstilimab.
OBT076 is a CD205-targeting antibody-drug conjugate (ADC) being evaluated in patients with advanced solid tumors and demonstrates a potential dual mechanism of action to re-engage the immune system and make more patients eligible for immunotherapies and checkpoint inhibitors.
We have also begun recruitment in Europe into the expansion cohorts of the Phase 1 trial investigating the safety, tolerability and pharmacokinetic profile of OBT076 as a monotherapy.
Find out more: https://lnkd.in/eTjxd5_c
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14